Lakeshore Biopharma Co. Ltd.Preferred / convertible
13F holders, Q1 2025 (March 31)18holders
1new positions
1sold out
1famous investor
$0.05avg. 13F price*
At the end of Q1 2025, 18 institutions reported holding Lakeshore Biopharma Co. Ltd. in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 1 sold out. The largest holders were LMR Partners LLP ($43K), Athos Capital Ltd ($32K) and Valliance Asset Management Ltd ($31K). One famous investor held it David E. Shaw ( of D. E. Shaw & Co.'s portfolio).
- Company
- Lakeshore Biopharma Co. Ltd.
- CUSIP
- G9845F117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 1 | $15K |
All 13F filers, Q4 2024 → Q1 2025: 107,006 shares bought and 150,544 shares sold, net −43,538 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| LMR Partners LLP | — | No change | 1,052,461 | $43K |
| Athos Capital Ltd | — | No change | 128,981 | $32K |
| Valliance Asset Management Ltd | — | No change | 750,000 | $31K |
| Jane Street Group, LLC | — | No change | 498,301 | $21K |
| Finepoint Capital LP | — | No change | 489,999 | $20K |
| Bracebridge Capital, LLC | — | No change | 232,323 | $10K |
| Calamos Advisors LLC | — | No change | 146,040 | $6K |
| Whitebox Advisors LLC | — | No change | 125,000 | $5K |
| Q Global Advisors, LLC | — | No change | 130,600 | $5K |
| Two Sigma Securities, LLC | — | New | 107,006 | $4K |
| D. E. Shaw & Co. | — | No change | 100,000 | $4K |
| Saba Capital Management, L.P. | — | No change | 97,299 | $4K |
| Walleye Capital LLC | — | No change | 95,030 | $4K |
| Cantor Fitzgerald, L. P. | — | No change | 76,931 | $3K |
| Clear Street LLC | — | Reduce -1.1% | 47,624 | $2K |
| SkyView Investment Advisors, LLC | — | No change | 12,210 | $1K |
| Ancora Advisors LLC | — | No change | 5,050 | $208 |
| HGC Investment Management Inc. | — | No change | 5,000 | $206 |
"% of holder's portfolio" is LAKESHORE BIOPHARMA CO LTD's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.